ASX Share rice
Tue 27 Oct 2020 - 05:45:pm (Sydney)

IMR Share Price

IMRICOR MEDICAL SYSTEMS, INC.IMRHealth Care Equipment & Services

IMR Company Information

Name:

Imricor Medical Systems, Inc

Sector:

Healthcare

Industry:

Medical Devices

Address:

400 Gateway Boulevard Burnsville MN United States 55337

Phone:

952 818 8400

CEO, Pres & Exec. Chairman:

Mr. Steve Wedan

CFO & VP of Fin.:

Ms. Lori Milbrandt

VP of Operations:

Mr. Gregg Stenzel

Director of Sales:

Mr. Greg Englehardt

Director of Marketing:

Mr. Nick Twohy

Company Overview:

Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States and Europe. The company's principal products include the Advantage-MR EP Recorder/Stimulator system, an electrophysiology amplifier and recording system with integrated cardiac stimulator; Vision-MR Ablation Catheter, which is used as an indication for treating type I atrial flutter; and Vision-MR Dispersive Electrode, an ablation dispersive electrode that is used to minimize eddy currents induced on the conductive pads during MR scanning. The company also performs contract research, as well as licenses its intellectual property for use in implantable devices. Imricor Medical Systems, Inc. was founded in 2006 and is headquartered in Burnsville, Minnesota.

IMR Share Price Information

Shares Issued:

112.64M

Market Capitalisation:

$274.84M

Revenue (TTM):

$862.69K

Revenue Per Share (TTM):

$0.01

Earnings per Share:

$-0.186

Operating Margin (TTM):

$-10.31

Return On Assets (TTM):

$-0.43

Return On Equity (TTM):

$-6.97

Quarterly Revenue Growth (YOY):

4.088

Gross Profit(TTM):

$262.34K

Diluted Earnings Per Share (TTM):

$-0.155

IMR CashFlow Statement

CashFlow Date:

2019-12-31

Investments:

$-755,549.53

Change To Liabilities:

$263.70K

Total Cashflow From Investing Activities:

$-529,340

Net Borrowings:

$3.23M

Net Income:

$-13,293,980

Total Cash From Operating Activities:

$-6,627,990

Depreciation:

$257.30K

Other Cashflow From Investing Activities:

$-164,580

Change To Inventory:

$-846,300

Change To Account Receivables:

$-160,968

Sale Purchase Of Stock:

$7.22M

Capital Expenditures:

$364.76K

IMR Income Statement

Income Date:

2019-12-31

Income Before Tax:

$-13,293,980

Net Income:

$-13,293,980

Gross Profit:

$262.33K

Operating Income:

$-12,479,360

Interest Expense:

$1.47M

Total Revenue:

$639.70K

Total Operating Expenses:

$18.21M

Cost Of Revenue:

$377.37K

IMR Balance Sheet

Balance Sheet Date:

2019-12-31

Total Liabilities:

$3.49M

Total Stockholder Equity:

$7.03M

Other Current Liabilities:

$554.64K

Total Assets:

$10.52M

Common Stock:

$9.27K

Retained Earnings:

$-40,425,700

Other Liabilities:

$592.85K

Other Assets:

$692.17K

Cash:

$7.21M

Total Current Liabilities:

$1.42M

Property - Plant & Equipment:

$2.74M

Net Tangible Assets:

$7.03M

Total Current Assets:

$6.81M

Net Receivables:

$256.29K

Short-Term Investments:

$5.29M

Inventory:

$1.22M

Accounts Payable:

$772.17K

Non Currrent Assets (Other):

$0.99M

Short-Term Investments:

$5.29

Non Current Liabilities (Other):

$2.43M

Non Current Liabilities Total:

$2.95M

IMR Share Price History

IMR News

05 Oct, 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
12 Aug, 2020
Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR), the global leader in MRI-guided cardiac ablation products, is pleased to announce a sales collaboration with Optoacoustics Ltd, the world leader in innovative, high performance optical communication solutions for magnetic resonance (MR) applications.
04 Aug, 2020
IMRICOR ANNOUNCES FIRST SALES COLLABORATION WITH PHILIPS.
08 Jul, 2020
The big shareholder groups in Imricor Medical Systems, Inc. (ASX:IMR) have power over the company. Institutions will...
11 Mar, 2020
Imricor Medical Systems, Inc.'s (ASX:IMR): Imricor Medical Systems, Inc., a medical device company, designs...
05 Feb, 2020
IMRICOR ANNOUNCES FIRST CASES SUCCESSFULLY PERFORMED AT HEART CENTER DRESDEN
27 Jan, 2020
Imricor Medical Systems, Inc. (ASX:IMR) today announces that it has received CE mark approval for its Vision-MR Ablation Catheter and Vision-MR Dispersive Electrode. This follows earlier CE mark approval for Imricor to place its Advantage-MR EP Recorder/Stimulator System on the market in Europe. Imricor is the first and only company to offer cardiac ablation devices for use in the MRI environment.